Symbol | Exchange | Currency |
|---|
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on uniQure (NASDAQ:QURE) N.V. on Tuesday, setting a price target of $71, which is approximately 122.08% above the...
RBC Capital analyst Luca Issi maintained a Buy rating on uniQure (NASDAQ:QURE) N.V. on Monday, setting a price target of $53, which is approximately 64.34% above the present share...
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (NASDAQ:QURE) N.V. on Monday, setting a price target of $100, which is approximately 209.79% above the...
uniQure (NASDAQ:QURE) QURE shares soared 8.3% in the last trading session to close at $34.95. The move was backed by solid volume with far more shares changing hands than in a...
The NASDAQ registered its first closing high in more than two months on Monday, as the market gets ready for an important week that will see four of the five FAANGs and other...
UniQure (QURE) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.97 per share a year ago. These...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,402.22 | 2,432.06 | 2,400.30 | -32.65 | -1.34% | 2.31M | NASDAQ | |||
| 329.66 | 336.15 | 329.00 | -6.85 | -2.04% | 23.04M | NASDAQ | |||
| 212.30 | 213.84 | 210.59 | +0.70 | +0.33% | 13.72M | NYSE | |||
| 59.26 | 64.96 | 56.85 | -1.47 | -2.42% | 243.65M | NYSE | |||
| 112.04 | 116.89 | 111.92 | -5.96 | -5.05% | 1.59M | NYSE | |||
| 318.57 | 322.08 | 314.00 | +5.96 | +1.91% | 564.30K | NASDAQ | |||
| 92.25 | 96.54 | 91.86 | -5.86 | -5.97% | 1.86M | NYSE | |||
| 25.37 | 25.94 | 25.02 | -0.08 | -0.31% | 65.85M | NYSE | |||
| 59.43 | 61.53 | 59.07 | -2.98 | -4.77% | 3.46M | NYSE | |||
| 8.74 | 9.05 | 8.63 | -0.46 | -5.00% | 16.89M | NYSE | |||
| 6.48 | 6.48 | 6.31 | -0.01 | -0.15% | 60.94K | NASDAQ | |||
| 28.42 | 28.87 | 28.18 | -0.35 | -1.22% | 6.17M | NYSE | |||
| 239.26 | 242.60 | 232.42 | +7.10 | +3.06% | 4.43M | NASDAQ | |||
| 28.67 | 28.74 | 28.02 | +0.03 | +0.10% | 25.01M | NYSE | |||
| 98.17 | 99.76 | 95.27 | +3.52 | +3.72% | 7.60M | NYSE |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
